---
title: "Mizuho Securities Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293125838.md"
description: "Mizuho Securities analyst Joseph Catanzaro reaffirmed a Buy rating on Tango Therapeutics (TNGX) with a $40 price target, noting the stock closed at $28.56. This aligns with a broader Strong Buy consensus averaging $42.67. Additionally, J.P. Morgan initiated coverage with a Buy rating and a $46 target on July 15."
datetime: "2026-07-19T12:15:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293125838.md)
  - [en](https://longbridge.com/en/news/293125838.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293125838.md)
---

# Mizuho Securities Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)

In a report released on July 17, Joseph Catanzaro from Mizuho Securities maintained a Buy rating on Tango Therapeutics, with a price target of $40.00. The company’s shares closed last Friday at $28.56.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Catanzaro is a 5-star analyst with an average return of 12.6% and a 46.01% success rate. Catanzaro covers the Healthcare sector, focusing on stocks such as Tango Therapeutics, Erasca, and Revolution Medicines.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tango Therapeutics with a $42.67 average price target, representing a 49.40% upside. In a report released on July 15, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $46.00 price target.

### Related Stocks

- [TNGX.US](https://longbridge.com/en/quote/TNGX.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [ERAS.US](https://longbridge.com/en/quote/ERAS.US.md)
- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [Tango Therapeutics Announces Executive Chair Transition | TNGX Stock News](https://longbridge.com/en/news/295154714.md)
- [Tango Therapeutics ajukan program penjualan saham at-the-market hingga USD 400 juta](https://longbridge.com/en/news/295581692.md)
- [Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities](https://longbridge.com/en/news/295597409.md)
- [Wedbush Reaffirms Their Hold Rating on Apogee Therapeutics (APGE)](https://longbridge.com/en/news/295552883.md)
- [Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)](https://longbridge.com/en/news/295099820.md)